Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Sun BioPharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sun BioPharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Sun BioPharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Sun BioPharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sun BioPharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Sun BioPharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Sun BioPharma's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Sun BioPharma's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Sun BioPharma is high growth as no earnings estimate data is available.
Unable to determine if Sun BioPharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Sun BioPharma's filings and announcements here.
Sun BioPharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Michael T. Cullen, Jr., M.D., M.B.A., is President and CEO at Sun BioPharma, Inc. since October 31, 2018. He co-founded Sun BioPharma, Inc. in November 2011 and served as its President from November 2011 to June 2015. Dr. Cullen has 30 years of pharmaceutical experience to Sun BioPharma, including expertise in working with development-stage companies in planning, designing and advancing drug candidates from preclinical through clinical development. Dr. Cullen served as Executive Officer at Sun BioPharma, Inc. and served as its President until April 2, 2016. Dr. Cullen served as Vice President and Medical Director of SunPharm Corporation since September 1998. Prior to that, Dr. Cullen served as a Vice President for Clinical consulting of IBAH Clinical Consulting Services from 1997 to 1998 and from 1995 to 1997 Vice President and Medical Director of IBAH U.S. Business Development. He Co-Founded Cimarron Medical, Inc. and served as its President and Chairman of the Board of Directors. Dr. Cullen has been Executive Chairman of the Board at Sun BioPharma, Inc. since September 4, 2011. Dr. Cullen worked at G.D. Searle, SunPharm Corporation. Dr. Cullen was a Co-founder of IDD Medical, Inc. and served as its Chief Executive Officer From 1994 to 1995. He served as Assistant and Associate Director for Clinical Research of 3M Pharmaceuticals from 1988 to 1994. Dr. Cullen practiced from 1977 to 1988 at Owatonna Clinic, Owatonna, MN, where he served as president. Dr. Cullen joined MGI PHARMA as Vice President, Clinical Affairs and Chief Medical Officer since September 7, 2000 until 2008. Dr. Cullen has three decades of medical and pharmaceutical industry experience. He served as a medical director for global medical operations and marketing of Searle/Pharmacia Corporation. Previously, he served as a Consultant in Internal medicine in Owatonna, Minnesota from 1977 to 1988 and served with the National Center for Disease Control from 1972 to 1974. He is certified by the American Board of Internal Medicine and practiced for more than a decade at the Owatonna Clinic, P.A. in Owatonna, Minnesota where he served as President. He is board certified in Internal medicine. Dr. Cullen received his BS and M.D. degrees from the University of Minnesota Medical School and his MBA from the University of St. Thomas, in St. Paul, Minnesota in 1991 and completed his residency and Board certification in Internal Medicine through the University of North Carolina in Chapel Hill and Wilmington, NC.
Michael's compensation has increased whilst company is loss making.
Michael's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Sun BioPharma management team is less than 2 years, this suggests a new team.
VP of Finance
Co-Founder & Chief Scientific Officer
Vice President of Operations
Chief Medical Officer & Director
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Sun BioPharma board of directors is about average.
Sun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with pancreatic cancer. The company has scientific collaborations with pancreatic disease experts Cedars Sinai Medical Center in Los Angeles, the University of Miami; the University of Florida; the Austin Health Cancer Trials Centre in Melbourne, Australia; the Ashford Cancer Centre in Adelaide, Australia; and the Blacktown Cancer and Haematology Centre in Sydney, Australia. Sun BioPharma, Inc. was founded in 2011 and is based in Waconia, Minnesota.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.